Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
AstraZeneca
Mallinckrodt
Merck
Medtronic

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR HYDROCORTISONE SODIUM SUCCINATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Hydrocortisone Sodium Succinate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002757 ↗ TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma Completed Children's Cancer and Leukaemia Group Phase 3 2001-06-01 RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.
NCT00002757 ↗ TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 3 2001-06-01 RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.
NCT00002757 ↗ TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma Completed Societe Francaise Oncologie Pediatrique Phase 3 2001-06-01 RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.
NCT00002757 ↗ TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma Completed Children's Oncology Group Phase 3 2001-06-01 RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.
NCT00002805 ↗ Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 2 1997-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome in first relapse or who did not achieve first remission.
NCT00002805 ↗ Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed Children's Oncology Group Phase 2 1997-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome in first relapse or who did not achieve first remission.
NCT00057811 ↗ Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma Completed National Cancer Institute (NCI) Phase 2 2004-06-01 Phase II trial to study the effectiveness of combining rituximab and rasburicase with combination chemotherapy in treating young patients who have newly diagnosed advanced B-cell leukemia or lymphoma. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug with rituximab may kill more cancer cells. Chemoprotective drugs such as rasburicase may protect kidney cells from the side effects of chemotherapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydrocortisone Sodium Succinate

Condition Name

Condition Name for Hydrocortisone Sodium Succinate
Intervention Trials
Leukemia 5
Untreated Childhood Acute Lymphoblastic Leukemia 4
Sepsis 3
Untreated Adult Acute Lymphoblastic Leukemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hydrocortisone Sodium Succinate
Intervention Trials
Leukemia 15
Leukemia, Lymphoid 14
Precursor Cell Lymphoblastic Leukemia-Lymphoma 14
Lymphoma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hydrocortisone Sodium Succinate

Trials by Country

Trials by Country for Hydrocortisone Sodium Succinate
Location Trials
United States 313
Canada 41
Australia 22
New Zealand 6
Puerto Rico 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hydrocortisone Sodium Succinate
Location Trials
California 11
Massachusetts 10
Ohio 10
New York 10
Oregon 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hydrocortisone Sodium Succinate

Clinical Trial Phase

Clinical Trial Phase for Hydrocortisone Sodium Succinate
Clinical Trial Phase Trials
Phase 3 9
Phase 2/Phase 3 1
Phase 2 9
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hydrocortisone Sodium Succinate
Clinical Trial Phase Trials
Completed 11
Active, not recruiting 5
Not yet recruiting 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hydrocortisone Sodium Succinate

Sponsor Name

Sponsor Name for Hydrocortisone Sodium Succinate
Sponsor Trials
National Cancer Institute (NCI) 10
Children's Oncology Group 4
Boston Children's Hospital 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hydrocortisone Sodium Succinate
Sponsor Trials
Other 37
NIH 10
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Dow
Medtronic
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.